Proteostasis Therapeutics Inc to Post Q1 2018 Earnings of ($0.49) Per Share, Leerink Swann Forecasts (PTI)
Proteostasis Therapeutics Inc (NASDAQ:PTI) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Proteostasis Therapeutics in a research report issued on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings of ($0.49) per share for the quarter. Leerink Swann also issued estimates for Proteostasis Therapeutics’ Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.46) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.89) EPS, FY2019 earnings at ($1.52) EPS and FY2020 earnings at ($1.57) EPS.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%.
Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Robert W. Baird raised their price target on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday.
Proteostasis Therapeutics (PTI) opened at $4.99 on Thursday. Proteostasis Therapeutics has a 12 month low of $1.41 and a 12 month high of $16.67.
A number of institutional investors have recently modified their holdings of the stock. LMR Partners LLP purchased a new position in Proteostasis Therapeutics in the 2nd quarter worth approximately $127,000. Goldman Sachs Group Inc. lifted its stake in Proteostasis Therapeutics by 364.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock worth $243,000 after purchasing an additional 40,731 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Proteostasis Therapeutics in the 2nd quarter worth approximately $254,000. Dimensional Fund Advisors LP purchased a new position in Proteostasis Therapeutics in the 2nd quarter worth approximately $296,000. Finally, Sabby Management LLC lifted its stake in Proteostasis Therapeutics by 109.6% in the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after purchasing an additional 65,451 shares in the last quarter. 68.08% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Proteostasis Therapeutics Inc to Post Q1 2018 Earnings of ($0.49) Per Share, Leerink Swann Forecasts (PTI)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2017/12/16/proteostasis-therapeutics-inc-to-post-q1-2018-earnings-of-0-49-per-share-leerink-swann-forecasts-pti.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.